They found that FTO can also regulate the immune microenvironment of tumor by regulating m6A methylation, inhibiting the expression of FTO through CS1 or CS2, and inhibiting the expression of immune checkpoint genes, such as leukocyte immunoglobulin like receptor B4 (LILRB4), which makes tumor cells more sensitive to toxic T cells, and significantly reduced the self-renewal of cancer cells by reprogramming immune response [161]. The gene discussed is FTO; the disease is neoplasm.